Physician profile
Katie Rush
NPI 1891183208
$368.09
in general payments reported to CMS, 2019-2025
12 companies · $46.04 in 2025
The $46.04 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.06 · 2022: $69.68 · 2023: $38.08 · 2024: $165 · 2025: $46.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $150.98 | 2024 | |
| Abbvie INC. | $41.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.23 | 2021 | |
| Mylan Specialty L.P. | $20.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.05 | 2023 | |
| Sumitomo Pharma America, INC. | $19.03 | 2023 | Aptiom |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.53 | 2025 | Caplyta |
| Hologic Sales and Service, LLC | $16.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.50 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $14.25 | 2024 | Trelegy Ellipta |
| Pfizer INC. | $14.01 | 2025 | |
| Abbott Laboratories | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.